Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ITUB4 has gained 11% in a week and 17% in a month, yet short sellers are still adding to positions, a split verdict that frames the key question into November earnings.
The HSBC downgrade published earlier today laid out the positioning story for the US-listed ADR ITUB. This note picks up where that left off, focusing on the preferred shares on BOVESPA. The lending market here offers almost no signal in either direction. Availability is at the maximum measurable level, with roughly 2.47 million shares available to borrow and a borrowing cost running below 0.30% annually. There is no short squeeze pressure, and no scarcity of supply for anyone wanting to add a new short. The ORTEX short score sits at 24.9, a low reading consistent with minimal short-side conviction in the lending data, and it has been flat for at least the past ten days. For the ITUB4 preferred line specifically, shorts are not the primary narrative.
Where the data is more interesting is in price and valuation. The price-to-book multiple has risen 0.31 points over the past month to 2.35x, and the PE has moved up 1.34 turns to 9.9x. Those are not stretched levels in absolute terms, but they represent a meaningful re-rating in a short period. HSBC's call on the ADR (price target equivalent of roughly $9.10 against a close near $9.74) was explicitly a valuation call after a 19% run. Factor scores add a little texture: the dividend rank scores 73, the days-to-cover rank is at the maximum of 100, and the short score rank of 98 confirms this is about as un-shorted a name as you will find in the ORTEX universe. There are no fresh analyst targets on the ITUB4 preferred line itself to cite, the most recent data predates this year, so the HSBC ADR downgrade stands as the best available read on Street direction.
Ownership is stable and heavily anchored. Itaúsa, the controlling shareholder, holds 46.3% of shares and made a modest net addition in late August, buying around 105,000 shares across two days before trimming slightly. The moves are small relative to the base and carry a significance score of 3, so they read more as routine portfolio management than a directional signal. Among international holders, Capital Research added roughly 11.5 million shares (reported to end-September) and Norges Bank added around 21.5 million (to end-June). BlackRock and Vanguard also added smaller amounts. Institutional flow is broadly supportive, with no major name trimming materially.
Peers on BOVESPA also pulled back sharply on Wednesday. ITSA4 fell 3.3% on the day and BBDC4 dropped 3.7%, wider than ITUB4's own 2.7% decline. BBAS3 held up better, losing less than 2%. The sector-wide dip after a strong run is consistent with profit-taking rather than stock-specific news.
The next earnings event is scheduled for 3 November. The most recent prior print, in early September, produced a 5.1% one-day gain and a 4.3% five-day gain. The August print went the other way, with a 0.6% decline on the day followed by an 8.7% drop over the subsequent week. The reaction pattern is not one-directional, which means positioning into the print matters. With shorts light, borrow costs negligible, and the stock up 17% in a month, the conversation heading into November is less about whether Itaú is growing and more about whether a re-rated multiple leaves room for further upside if the credit quality and net interest margin numbers simply meet expectations.
See the live data behind this article on ORTEX.
Open ITUB4 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
